10:43 AM EST - Willow Biosciences : And SUANFARMA today jointly announced that they have, together with SUANFARMA's CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol. The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023. Willow Biosciences
shares T.WLLW are trading unchanged at $0.09.
